4.6 Review

Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review)

Journal

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
Volume 42, Issue 3, Pages 1203-1214

Publisher

SPANDIDOS PUBL LTD
DOI: 10.3892/ijmm.2018.3744

Keywords

EP2; mechanism; cancer; invasion; inflammation

Funding

  1. International Cooperation Key Project of the National Natural Science Foundation of China [81520108031]
  2. Science Foundation of Shanghai Committee of Science Project [14430722900]
  3. Program for Outstanding Medical Academic Leader and Shanghai Academic Research Leader [16XD1403600]

Ask authors/readers for more resources

Prostaglandin E2 (PGE2) receptor 2 subtype (EP2), which is a metabolite of arachidonic acid that binds with and regulates cellular responses to PGE2, is associated with numerous physiological and pathological events in a wide range of tissues. As a stimulatory G protein-coupled receptor, PGE2-induced EP2 activation can activate adenylate cyclase, leading to increased cytoplasmic cAMP levels and activation of protein kinase A. The EP2 receptor can also activate the glycogen synthase kinase 3 beta and beta-catenin pathways. The present study aimed to review the roles of the EP2 receptor in tumor development, including immunity, chronic inflammation, angiogenesis, metastasis and multidrug resistance. Furthermore, the involvement of the EP2 receptor signaling pathway in cancer was discussed. Understanding the role and mechanisms of action of the EP2 receptor, and its importance in targeted therapy, may help identify novel methods to improve management of numerous types of cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available